HepG2 (Human hepatocellular liver carcinoma cell line) Cytoplasmic Lysate (ab14659)
- Product nameHepG2 (Human hepatocellular liver carcinoma cell line) Cytoplasmic LysateSee all HepG2 lysates ...
- General notesWe recommend aliquoting the extracts into single use fractions and then storing them.
- Tested applicationsWB, EMSA more details
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
- Storage bufferpH: 7.90
Constituents: 0.48% HEPES, 0.75% Potassium chloride, 0.01% Magnesium chloride, 20% Glycerol, 0.009% PMSF, 0.008% DTT
- Concentration information loading...
- PurityWhole Cell Lysate
- Research Areas
- BackgroundHepatitis B virus (HBV) is the major cause of acute and chronic hepatitis, leading to progressive development of necroinflammatory changes in the liver, which can result in cirrhosis and hepatocellular carcinoma. Although the development of an effective vaccine to prevent HBV infection has shown promising results and should lead to its eventual eradication, antiviral chemotherapy remains the only effective method to prevent the progression of the disease in chronic carriers. Therefore, the development of new antiretroviral agents active against HBV is needed. HepG2 cells have an epithelial morphology and are thought to be a very useful model to study HBV virus replication via transfection. Cells are also used for cancer and apoptosis studies (in particular signalling pathway studies).
Our Abpromise guarantee covers the use of ab14659 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Not tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
References for HepG2 (Human hepatocellular liver carcinoma cell line) Cytoplasmic Lysate (ab14659)
ab14659 has not yet been referenced specifically in any publications.